What were the main findings of the SYNCHRONIZE-1 trial for survodutide?

The SYNCHRONIZE-1 trial showed that survodutide led to significant weight loss, with participants losing an average of 39.2 lb. (17.8 kg) over 76 weeks, and also reduced waist circumference.

How does survodutide work?

Survodutide is a dual-action glucagon/GLP-1 receptor agonist that works by decreasing appetite and increasing fullness, while also potentially acting on the liver to reduce fat and improve metabolic function.

Home / Health / Survodutide Trial Reveals Major Weight Loss Success

Survodutide Trial Reveals Major Weight Loss Success

Q: When will more data on survodutide be available?

Full data from the Phase III SYNCHRONIZE-1 trial will be presented at the upcoming American Diabetes Association's (ADA) 2026 Scientific Sessions in June.

29 Apr

•

Summary

Survodutide trial participants lost an average of 39.2 lb.
Drug showed significant waist circumference reduction.
Survodutide may also support liver function.

Survodutide Trial Reveals Major Weight Loss Success

Boehringer Ingelheim has announced positive topline results from its Phase III SYNCHRONIZE-1 trial for survodutide, a novel treatment for obesity. Adults treated with survodutide experienced substantial weight loss, with an average reduction of 39.2 lb. (17.8 kg) over 76 weeks, significantly outperforming placebo. The trial met its co-primary endpoints for both weight reduction and achieving at least a 5% body weight decrease.

Beyond weight loss, survodutide demonstrated a statistically significant reduction in waist circumference, a crucial marker for cardiometabolic risk. This dual-action glucagon/GLP-1 receptor agonist also shows potential in supporting liver function, addressing a key aspect of metabolic health. Full data will be presented at the upcoming American Diabetes Association's Scientific Sessions.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.